Document is current
Any future updates will be listed below
-
Authors
Charles-Schoeman, Christina https://orcid.org/0000-0002-1768-7019
Wang, Jennifer
Shahbazian, Ani
Wilhalme, Holly https://orcid.org/0000-0002-8434-6548
Brook, Jenny https://orcid.org/0000-0001-5705-1042
Kaeley, Gurjit S. https://orcid.org/0000-0003-1335-3131
Oganesian, Buzand
Ben-Artzi, Ami
Elashoff, David A. https://orcid.org/0000-0002-5865-8580
Ranganath, Veena K. https://orcid.org/0000-0003-3417-9478
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01717859 at ClinicalTrials.govnct01299961 at ClinicalTrials.govDocuments that mention this clinical trial
Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis
https://doi.org/10.1007/s00296-023-05285-7
Documents that mention this clinical trial
Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis
https://doi.org/10.1007/s00296-023-05285-7
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb Foundation (IM101-273)
Genentech (ML28542)
NHLBI Division of Intramural Research (R01HL123064)
- License Information
-
More Information
Article History
Received: 24 October 2022
Accepted: 31 January 2023
First Online: 24 February 2023
Declarations
:
: Dr. Charles-Schoeman received grants from Pfizer, Bristol-Meyers Squibb, AbbVie, and consulting fees from Pfizer, AbbVie, Regneron-Sanofi and Gilead. Dr. Ranganath has received grants and research support from Bristol-Myers Squibb and Mallinckrodt, and consulting with Horizon, Gilead, Janssen, and Genentech. The other authors have disclosed no conflicts of interest.
: The study was approved by the UCLA institutional review board (IRB#12-001547 and IRB#11-000152).
